Dr Daniel J Weiss, MD PHD | |
111 Colchester Ave, Burlington, VT 05405-0001 | |
(802) 847-6177 | |
Not Available |
Full Name | Dr Daniel J Weiss |
---|---|
Gender | Male |
Speciality | Pulmonary Disease |
Experience | 36 Years |
Location | 111 Colchester Ave, Burlington, Vermont |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1396858023 | NPI | - | NPPES |
1008077 | Medicaid | VT | |
02175244 | Medicaid | NY |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RC0200X | Internal Medicine - Critical Care Medicine | 042-0010286 (Vermont) | Primary |
207RP1001X | Internal Medicine - Pulmonary Disease | 042-0010286 (Vermont) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Univ. Of Vermont - Fletcher Allen Health Care | Burlington, VT | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
University Of Vermont Medical Center Inc | 3779491071 | 994 |
News Archive
Left atrial fibrosis may explain the increased risk of arrhythmias seen in highly trained endurance athletes, according to research presented today at ESC Congress 2018.
The U.S. Food and Drug Administration has approved Somatuline Depot (lanreotide acetate injection) for the treatment of acromegaly, a rare and potentially life threatening disease in adults caused by abnormal secretion of growth hormone (GH), commonly from a benign tumor located in the pituitary gland located in the brain.
Affymetrix, Inc. today announced that the U.S. Food and Drug Administration has cleared the addition of new gene expression reagents as accessories to its GeneChip Microarray Instrument System for in vitro diagnostic use, making Affymetrix the first in the industry to provide a comprehensive microarray-based clinical toolkit for diagnostic test development, signature discovery for companion diagnostics, and translational initiatives. Affymetrix Gene Profiling Reagents offer unparalleled convenience by simplifying assay workflow, decreasing hands-on time, and reducing quality control testing compared to research-use-only-produced products.
In a new study published in Cancer Letters, American University researchers show how, as body mass index increases, so does the growth and spread of the blood cancer multiple myeloma, which accounts for about 10 percent of all blood cancers in patients.
Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of a New Drug Application (NDA) for ezetimibe and atorvastatin tablets, an investigational combination medicine.
› Verified 6 days ago
Entity Name | University Of Vermont Medical Center Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1659309615 PECOS PAC ID: 3779491071 Enrollment ID: O20040406001047 |
News Archive
Left atrial fibrosis may explain the increased risk of arrhythmias seen in highly trained endurance athletes, according to research presented today at ESC Congress 2018.
The U.S. Food and Drug Administration has approved Somatuline Depot (lanreotide acetate injection) for the treatment of acromegaly, a rare and potentially life threatening disease in adults caused by abnormal secretion of growth hormone (GH), commonly from a benign tumor located in the pituitary gland located in the brain.
Affymetrix, Inc. today announced that the U.S. Food and Drug Administration has cleared the addition of new gene expression reagents as accessories to its GeneChip Microarray Instrument System for in vitro diagnostic use, making Affymetrix the first in the industry to provide a comprehensive microarray-based clinical toolkit for diagnostic test development, signature discovery for companion diagnostics, and translational initiatives. Affymetrix Gene Profiling Reagents offer unparalleled convenience by simplifying assay workflow, decreasing hands-on time, and reducing quality control testing compared to research-use-only-produced products.
In a new study published in Cancer Letters, American University researchers show how, as body mass index increases, so does the growth and spread of the blood cancer multiple myeloma, which accounts for about 10 percent of all blood cancers in patients.
Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of a New Drug Application (NDA) for ezetimibe and atorvastatin tablets, an investigational combination medicine.
› Verified 6 days ago
Entity Name | Central Vermont Medical Center Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1831374362 PECOS PAC ID: 9335138817 Enrollment ID: O20040510001034 |
News Archive
Left atrial fibrosis may explain the increased risk of arrhythmias seen in highly trained endurance athletes, according to research presented today at ESC Congress 2018.
The U.S. Food and Drug Administration has approved Somatuline Depot (lanreotide acetate injection) for the treatment of acromegaly, a rare and potentially life threatening disease in adults caused by abnormal secretion of growth hormone (GH), commonly from a benign tumor located in the pituitary gland located in the brain.
Affymetrix, Inc. today announced that the U.S. Food and Drug Administration has cleared the addition of new gene expression reagents as accessories to its GeneChip Microarray Instrument System for in vitro diagnostic use, making Affymetrix the first in the industry to provide a comprehensive microarray-based clinical toolkit for diagnostic test development, signature discovery for companion diagnostics, and translational initiatives. Affymetrix Gene Profiling Reagents offer unparalleled convenience by simplifying assay workflow, decreasing hands-on time, and reducing quality control testing compared to research-use-only-produced products.
In a new study published in Cancer Letters, American University researchers show how, as body mass index increases, so does the growth and spread of the blood cancer multiple myeloma, which accounts for about 10 percent of all blood cancers in patients.
Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of a New Drug Application (NDA) for ezetimibe and atorvastatin tablets, an investigational combination medicine.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Daniel J Weiss, MD PHD 14 Hubbells Falls Dr, Essex Junction, VT 05452-4367 Ph: () - | Dr Daniel J Weiss, MD PHD 111 Colchester Ave, Burlington, VT 05405-0001 Ph: (802) 847-6177 |
News Archive
Left atrial fibrosis may explain the increased risk of arrhythmias seen in highly trained endurance athletes, according to research presented today at ESC Congress 2018.
The U.S. Food and Drug Administration has approved Somatuline Depot (lanreotide acetate injection) for the treatment of acromegaly, a rare and potentially life threatening disease in adults caused by abnormal secretion of growth hormone (GH), commonly from a benign tumor located in the pituitary gland located in the brain.
Affymetrix, Inc. today announced that the U.S. Food and Drug Administration has cleared the addition of new gene expression reagents as accessories to its GeneChip Microarray Instrument System for in vitro diagnostic use, making Affymetrix the first in the industry to provide a comprehensive microarray-based clinical toolkit for diagnostic test development, signature discovery for companion diagnostics, and translational initiatives. Affymetrix Gene Profiling Reagents offer unparalleled convenience by simplifying assay workflow, decreasing hands-on time, and reducing quality control testing compared to research-use-only-produced products.
In a new study published in Cancer Letters, American University researchers show how, as body mass index increases, so does the growth and spread of the blood cancer multiple myeloma, which accounts for about 10 percent of all blood cancers in patients.
Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of a New Drug Application (NDA) for ezetimibe and atorvastatin tablets, an investigational combination medicine.
› Verified 6 days ago
Nadia Ghallab, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 | |
Beach Conger, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 617 Riverside Ave, Burlington, VT 05401 Phone: 802-864-6309 Fax: 802-860-4313 | |
Dr. Christopher Dwight Huston, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-2264 | |
Beth Diane Kirkpatrick, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 111 Colchester Ave, Fletcher Allen Health Care, Burlington, VT 05401 Phone: 802-847-4594 | |
Dr. Richard Frank Branda, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1 S. Prospect St, Burlington, VT 05401 Phone: 802-847-3827 Fax: 802-847-3510 | |
Lauren Suggs, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 | |
Magdalena Anna Zeglin, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 |